Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 09 Feb 2018
At a glance
- Drugs Alisertib (Primary)
- Indications Mesothelioma
- Focus Therapeutic Use
- 06 Feb 2018 Planned End Date changed from 1 May 2021 to 1 May 2022.
- 15 Feb 2017 Planned End Date changed from 1 Feb 2021 to 1 May 2021.
- 15 Feb 2017 Status changed from recruiting to active, no longer recruiting.